- Home
- SCYX vs PULM Comparison
SCYX vs PULM Comparison
Compare SCYX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- PULM
- Stock Information
- Founded
- SCYX 1999
- PULM 2003
- Country
- SCYX United States
- PULM United States
- Employees
- SCYX N/A
- PULM N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- PULM Health Care
- Exchange
- SCYX Nasdaq
- PULM Nasdaq
- Market Cap
- SCYX 28.5M
- PULM 33.2M
- IPO Year
- SCYX 2014
- PULM N/A
- Fundamental
- Price
- SCYX $0.82
- PULM $6.55
- Analyst Decision
- SCYX
- PULM
- Analyst Count
- SCYX 0
- PULM 0
- Target Price
- SCYX N/A
- PULM N/A
- AVG Volume (30 Days)
- SCYX 176.2K
- PULM 59.3K
- Earning Date
- SCYX 08-07-2025
- PULM 08-12-2025
- Dividend Yield
- SCYX N/A
- PULM N/A
- EPS Growth
- SCYX N/A
- PULM N/A
- EPS
- SCYX N/A
- PULM N/A
- Revenue
- SCYX $2,630,000.00
- PULM $1,921,000.00
- Revenue This Year
- SCYX $463.61
- PULM N/A
- Revenue Next Year
- SCYX $310.80
- PULM $134.88
- P/E Ratio
- SCYX N/A
- PULM N/A
- Revenue Growth
- SCYX N/A
- PULM N/A
- 52 Week Low
- SCYX $0.66
- PULM $1.78
- 52 Week High
- SCYX $2.29
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- PULM 42.38
- Support Level
- SCYX $0.67
- PULM $6.28
- Resistance Level
- SCYX $0.75
- PULM $6.96
- Average True Range (ATR)
- SCYX 0.04
- PULM 0.48
- MACD
- SCYX 0.01
- PULM -0.07
- Stochastic Oscillator
- SCYX 93.53
- PULM 16.78
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).